Phlow announced today that it received $354 million in U.S. government funding to manufacture essential medicines at risk of shortage, including those involved in the COVID-19 pandemic response. This Covid-19 medications will be a helping aid to succeed against this terrible virus.
Phlow, a pharmaceutical company, made a significant announcement today, revealing that it has secured $354 million in funding from the U.S. government. This substantial investment is earmarked for the production of crucial COVID-19 medications, as part of the broader effort to combat the ongoing pandemic. The funding reflects the government’s commitment to supporting initiatives aimed at bolstering pandemic response efforts, ensuring access to essential treatments for those affected by the virus.
Phlow’s receipt of this funding underscores the pivotal role that pharmaceutical companies play in addressing global health crises, highlighting the collaborative efforts between public and private sectors in navigating these challenging times.”
Richmond, Va.-based Phlow’s manufacturing is being funded by the Biomedical Advanced Research and Development Authority, part of the office of Assistant Secretary for Preparedness and Response at the U.S. Dept. of Health and Human Services.
Source: DrugDiscoverytrends.com
Brought to you by Fomat Medical
Add a Comment